CLChristophe Legendre

Christophe Legendre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christophe Legendre has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PREventing Delayed Graft Function by Driving Immunosuppressive InduCtion Treatment (PREDICT-DGF): study protocol for a randomized controlled trial

    by Marion Chapal, Yohann Foucher, Monique Marguerite, Karine Neau, Emmanuelle Papuchon, Pascal Daguin, Emmanuel Morélon, Georges Mourad, Elisabeth Cassuto, Marc Ladrière, et al.

    In kidney transplantation, the use of Anti-Thymocyte Globulins (ATG) as induction therapy has been described as a possible treatment for reducing the prevalence of Delayed Graft Function (DGF). ATG possesses pharmaceutical proprieties that could help control the lesions caused by ischemia reperfusion injury. However, other studies have questioned this potential protective effect. We hypothesized that the benefits related to ATG for reducing DGF prevalence may be higher and more consistently recognized if only patients with high DGF risk are considered. We recently proposed a scoring system entitled DGFS (Delayed Graft Function Score) for such stratification of kidney transplant recipients according to their risk of DGF. Using the DGFS calculation, we aim to determine whether a short course of ATG can decrease the incidence of DGF in comparison with Basiliximab in kidney transplant recipients with low immunological risk but high DGF risk. We conduct a phase IV, open label, randomized, multicentric and prospective study, to compare ATG in parallel with a control group treated by Basiliximab. The 1:1 randomized allocation of patients between groups is stratified on the clinical center, and on the hypothermic machine-perfusion device. We aimed to include a total of 384 patients to achieve a statistical power at 0.80. The study was initiated at the Nantes University hospital in July 2014, with data collection continuing until April 2018, and publication of the results proposed for 2019. The main expected benefits of this study are i) the reduction of unjustified ATG over-prescriptions associated with serious adverse events, ii) the reduction of chance losses related to ATG under-prescription, iii) the decrease in the incidence of DGF which was described as a risk factor of graft failure and patient death, and iv) the reduction in hospitalization duration and number of post transplantation dialysis sessions, both being associated with reduced medical costs. In conclusion, the current study is innovative by proposing a more efficient and personalized induction therapy. The study was registered in the Clinical Trials Registry (# NCT02056938 , February 5, 2014), and in the European Clinical Trials Database (EudraCT #2014-000332-42, January 30, 2014).


  • Open Access

    A personalized follow-up of kidney transplant recipients using video conferencing based on a 1-year scoring system predictive of long term graft failure (TELEGRAFT study): protocol for a randomized controlled trial

    by Yohann Foucher, Aurélie Meurette, Pascal Daguin, Angélique Bonnaud-Antignac, Jean-Benoît Hardouin, Sabrina Chailan, Karine Neau, Emmanuelle Papuchon, Sandra Gaboriau, Christophe Legendre, et al.

    Numerous well-established clinical parameters are taken into consideration for the follow-up adaptation of kidney transplant recipients, but there are important disparities between countries, centres and clinicians. Therefore, novel scoring systems have been developed, for instance the Kidney Transplant Failure Score (KTFS) which aims to stratify patients according to their risk of return to dialysis. We hypothesize that the efficiency of the follow-up after one year post-transplantation can be improved by adapting it to the risk of graft failure defined by the KTFS estimation. We propose a phase IV, open label, randomized, multicentric and prospective study. The study is registered with the Clinical Trials Registry NCT01615900. 250 patients will be allocated to one of two arms: the eHealth program versus the standard of care at hospital. In the standard group, patients classified at low-risk (KTFS ≤ 4.17) will be scheduled 4 visits at hospital per year, whilst high-risk patients will visit hospital 6 times. In the eHealth group, patients classified at low-risk will be interviewed 3 times by video conferencing and once at hospital, whilst 6 visits at hospital and 6 video conferencing will be scheduled for high-risk patients. The current study allows to scientifically evaluate the etiologic impact of a novel eHealth program. This is important to clarify the possible contribution of telemedicine in the improvement of medical follow-up. The proposed design based on 4 different sub-groups can be interesting to evaluate other personalized medicine programs.


  • The DGFS: a Useful Scoring System for the Prediction and Management of Delayed Graft Function Following Kidney Transplantation From Cadaveric Donors.

    by M. Chapal, F. Le Borgne, C. Legendre, H. Kreiss, G. Mourad, E. Morelon, L. Rostaing, M. Kessler, M. Giral, Y. Foucher

  • Importance du suivi de la protéinurie chez le transplanté

    by C. Legendre

    The occurrence of proteinuria in transplant patients is a marker of poor prognosis. The augmentation of proteinuria is associated with an increased risk of patient death and graft loss. Even a low-level urinary protein excretion (0.5 g/d) has a highly significant negative impact on graft survival whether it is observed 1 or 3 months after transplantation. Urinary albumin excretion rate has also a major effect on risks of graft loss and death with functional kidney, macro-albuminuria increasing the risks of respectively 16.4 and 4.12 times comparatively to micro-albuminuria, which itself multiplies the risks by 14.2 and 5.5 respectively, compared to normo-albuminuria. In terms of factors causing proteinuria apparition, the role of proliferation signal inhibitors has been recently observed. Sirolimus, especially at high dose, in particular can induce the occurrence of proteinuria, which is reversible with treatment discontinuation, but only with a partial recovery of the renal function. Proteinuria may be explained by a direct glomerular impact of sirolimus on several podocyte markers.

  • Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus‐based therapy: a multivariate analysis of results at five years1

    by Christophe Legendre, Yves Brault, José M. Morales, Rainer Oberbauer, Paolo Altieri, Hany Riad, John Mahony, Maria Messina, Bruce Pussell, Javier G. Martínez, et al.

    Changes in calculated glomerular filtration rate (GFR) from baseline to five yr were analyzed in relation to risk factors among renal transplant recipients. At three months after transplantation (baseline), 430 eligible patients receiving sirolimus (SRL), cyclosporine (CsA), and steroids (ST) were randomly assigned (1:1) to continue SRL–CsA–ST or have CsA withdrawn and SRL trough levels increased (SRL–ST group). For each risk factor, changes from baseline were compared within each treatment using a t‐test and between treatments using ANCOVA. Univariate then multivariate robust linear regression analyses were also performed. In the SRL–ST group, changes from baseline were not significantly different for any risk factor. With the exception of cold ischemia time >24 h, GFR values declined significantly for all risk factors in SRL–CsA–ST patients. For all risk factors, except second transplant or cold ischemia time >24 h, renal function was significantly different between groups. By order of significance in the multivariate analysis, treatment (p < 0.001), donor age (p < 0.001), proteinuria (p < 0.001), and biopsy‐confirmed rejection (p = 0.010) were significant predictors of GFR change from baseline. In conclusion, patients with risk factors for reduced renal function benefit from SRL maintenance therapy without CsA vs. those remaining on CsA.


  • Proteinuria Following a Switch from Calcineurin Inhibitors to Sirolimus

    by Emmanuel Letavernier, Marie-Noëlle Pe’raldi, Antoine Pariente, Emmanuel Morelon, Christophe Legendre

    Background. Sirolimus is an alternative option for kidney transplant patients treated with calcineurin inhibitors (CNI) when renal function is deteriorating. However, the incidence of proteinuria following a switch from CNI to sirolimus has caused concern, and was therefore investigated here. Methods. In a retrospective study, 68 renal transplant recipients were switched from CNI to sirolimus. Proteinuria was measured using 24-hour urine collection before the switch and collections 3, 6, 12, and 24 months thereafter. In addition, proteinuria was measured in patients who had to be switched back to CNI due to side effects. Survival analyses were performed. Results. Baseline proteinuria was 0.39±0.69 g/day in all 68 patients. It increased to a mean 1.44±1.90 g/day at 3 months (PP<0.05). Proteinuria above 0.3 g/day before the CNI-sirolimus switch correlated significantly with the decrease of renal function thereafter. Conclusion. CNI-treated kidney transplant recipients may develop reversible proteinuria when switched to sirolimus.


    • 1 January 1988
      • Vol. 9  (1) , 33-5

    [Acute cytomegalovirus glomerulonephritis in a renal transplant patient].

    by C Legendre, G Mourad, P Baldet, C Mion

    We report on an acute glomerulonephritis with renal failure in a living-related renal allograft recipient with a cytomegalovirus infection. The clinical presentation was typical of an acute nephritis. Renal biopsy showed lesions of diffuse endocapillary proliferative glomerulonephritis. The disease resolved spontaneously. The pathogenesis of cytomegalovirus glomerulopathy is briefly discussed.